Current and historical daily PE Ratio for Paratek Pharmaceuticals Inc (
) from 2007 to Jun 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Paratek Pharmaceuticals stock (FRA:N4CN) PE ratio as of Jun 10 2024 is 0.
More Details
Paratek Pharmaceuticals Inc (FRA:N4CN) PE Ratio (TTM) Chart
Paratek Pharmaceuticals Inc (FRA:N4CN) PE Ratio (TTM) Historical Data
View and export this data going back to 2007. Start your Free Trial
Total 1078
- 1
- 2
- 3
- 4
- 5
- 6
- 12
| Paratek Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-10 | At Loss | 2023-07-20 | At Loss |
| 2023-09-21 | At Loss | 2023-07-19 | At Loss |
| 2023-09-20 | At Loss | 2023-07-18 | At Loss |
| 2023-09-19 | At Loss | 2023-07-17 | At Loss |
| 2023-09-18 | At Loss | 2023-07-14 | At Loss |
| 2023-09-15 | At Loss | 2023-07-13 | At Loss |
| 2023-09-14 | At Loss | 2023-07-12 | At Loss |
| 2023-09-13 | At Loss | 2023-07-11 | At Loss |
| 2023-09-12 | At Loss | 2023-07-10 | At Loss |
| 2023-09-11 | At Loss | 2023-07-07 | At Loss |
| 2023-09-08 | At Loss | 2023-07-06 | At Loss |
| 2023-09-07 | At Loss | 2023-07-05 | At Loss |
| 2023-09-06 | At Loss | 2023-07-04 | At Loss |
| 2023-09-05 | At Loss | 2023-07-03 | At Loss |
| 2023-09-04 | At Loss | 2023-06-30 | At Loss |
| 2023-09-01 | At Loss | 2023-06-29 | At Loss |
| 2023-08-31 | At Loss | 2023-06-28 | At Loss |
| 2023-08-30 | At Loss | 2023-06-27 | At Loss |
| 2023-08-29 | At Loss | 2023-06-26 | At Loss |
| 2023-08-28 | At Loss | 2023-06-23 | At Loss |
| 2023-08-25 | At Loss | 2023-06-22 | At Loss |
| 2023-08-24 | At Loss | 2023-06-21 | At Loss |
| 2023-08-22 | At Loss | 2023-06-20 | At Loss |
| 2023-08-21 | At Loss | 2023-06-19 | At Loss |
| 2023-08-18 | At Loss | 2023-06-16 | At Loss |
| 2023-08-17 | At Loss | 2023-06-15 | At Loss |
| 2023-08-16 | At Loss | 2023-06-14 | At Loss |
| 2023-08-15 | At Loss | 2023-06-13 | At Loss |
| 2023-08-14 | At Loss | 2023-06-12 | At Loss |
| 2023-08-11 | At Loss | 2023-06-09 | At Loss |
| 2023-08-10 | At Loss | 2023-06-08 | At Loss |
| 2023-08-09 | At Loss | 2023-06-07 | At Loss |
| 2023-08-08 | At Loss | 2023-06-06 | At Loss |
| 2023-08-07 | At Loss | 2023-06-05 | At Loss |
| 2023-08-04 | At Loss | 2023-06-02 | At Loss |
| 2023-08-03 | At Loss | 2023-06-01 | At Loss |
| 2023-08-02 | At Loss | 2023-05-30 | At Loss |
| 2023-08-01 | At Loss | 2023-05-29 | At Loss |
| 2023-07-31 | At Loss | 2023-05-26 | At Loss |
| 2023-07-28 | At Loss | 2023-05-25 | At Loss |
| 2023-07-27 | At Loss | 2023-05-24 | At Loss |
| 2023-07-26 | At Loss | 2023-05-22 | At Loss |
| 2023-07-25 | At Loss | 2023-05-19 | At Loss |
| 2023-07-24 | At Loss | 2023-05-18 | At Loss |
| 2023-07-21 | At Loss | 2023-05-17 | At Loss |
Paratek Pharmaceuticals Inc (FRA:N4CN) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Paratek Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US6993743029
Description
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers